STE — tear sheet

The engine assesses a Hold, calling the evidence a genuine standoff rather than a directional signal. The constructive side rests on management's 8-K press release (2026-08-05): fiscal 2027 first-quarter revenue up 7% to $1.5 billion, 6% constant-currency organic growth, adjusted diluted EPS of $2.59 versus $2.34, and full-year expectations explicitly unchanged; the engine finds no guidance cut, demand deterioration, or franchise erosion in the documents. No upgrade trigger is confirmed: the QuantOrb BUY flag (strength 0.8077) at an MFI of 8.33 is, per the vendor, a quantitative screen 'not a recommendation'; the 13F adds come from a non-exhaustive quarter-end snapshot as of 2026-03-31 (THIRTEENF); momentum is weak per the engine's risk review, with an RSI lower low, a widening MACD histogram and rolling moving averages; and free-cash-flow yield sits near parity with the 10-year yield per the engine's valuation check. The engine therefore frames the stance at no more than half standard weight, balanced at maintain-and-wait. Sources: EIGHTK (SEC 8-K press release); FACTS (QuantOrb snapshot); THIRTEENF (13F dataset); engine outputs.

Source: SEC 13F-HR holdings (as of 2026-03-31) via quantorb filers data — quarter-end snapshots, statutory lag up to 45 days

Quarter-end 13F-HR snapshot for STE as tracked in the quantorb filers dataset (5 institutional filer rows on file; positions as of 2026-03-31, a quarter-end snapshot subject to the statutory 13F reporting lag of up to 45 days). Quarter-over-quarter share changes where the dataset carries them:

This is the dataset's tracked top-holder snapshot, not an exhaustive list of 13F filers; it is a periodic regulatory disclosure, not real-time portfolio data.

Management's tone in the 8-K Item 2.02 press release (2026-08-05) is constructive: CEO Dan Carestio said the company is 'pleased with our performance,' citing 'stable underlying demand,' meaningful Healthcare-segment growth, share gains in consumables and services, and solid capital-equipment order growth; revenue and earnings expectations for the year were described as unchanged. The release reports first-quarter revenue of $1.5 billion (up 7%), GAAP diluted EPS of $2.04 (up from $1.79) and adjusted EPS of $2.59 (up from $2.34), and announces a targeted restructuring plan tied to a new Formulated Chemistries Center of Excellence in North Carolina. The 10-K (filed 2026-05-29) describes three reportable segments — Healthcare, AST and Life Sciences — after the fiscal 2025 Dental divestiture, presented as discontinued operations. Catalysts visible in the corpus, per the engine: the early-November fiscal Q2 report, the October 16 put expiry, and the CPI/rate path; restructuring charges land over the remaining three quarters. Sources: SEC 8-K Item 2.02 press release 2026-08-05 (EIGHTK); SEC 10-K filed 2026-05-29 (FILING); engine outputs.

The engine's risk review flags momentum and rates as key risks: RSI printed a lower low at 25.55, the MACD histogram widened six sessions, the 50- and 200-day moving averages rolled over, and 2.4x-average-volume distribution occurred into the low, with price pinned against the twice-tested 197.4–200.6 wick zone while nearest resistance at 208–213 compresses near-term reward-to-risk toward roughly 1:1. Macro risk centers on the 10-year Treasury touching 5.01% on September 16 before easing to 4.94%, with CPI re-accelerating about 0.4% month over month, per the engine. Growth-quality flags include Q1 free cash flow down 14.3%, inventory up 12.5% against roughly 7.3% revenue growth, a tax rate drifting from 21.3% toward 26.5%, and restructuring charges over the remaining three quarters. Evidence-quality risks: the QuantOrb flag is a contrarian oversold screen the vendor labels 'not a recommendation,' and the 13F data are a non-exhaustive quarter-end snapshot subject to a reporting lag of up to 45 days (THIRTEENF). Sources: engine risk review and technical report outputs; QuantOrb snapshot (FACTS); quantorb 13F-HR dataset (THIRTEENF).